{"product_id":"pasg-ansoff-analysis","title":"(PASG) Passage Bio, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Passage Bio, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification to help with research, strategy, investing, or planning; the page already includes a real preview\/sample of the analysis so you can judge style and substance before buying — purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBGM01 GM1 specialist centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBGM01 targets infantile GM1 gangliosidosis with an AAVhu68 capsid and a functional GLB1 gene, so market penetration means winning share inside the same pediatric neurology and lysosomal-disease centers that already see GM1. In an ultra-rare disease, the addressable clinical network is small, so deeper center-level visibility can matter more than broad reach. The play is tighter referral flow, stronger investigator ties, and faster patient identification within the existing GM1 community.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBFT02 FTD-GRN neurology network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBFT02 uses an AAV1 capsid to deliver a functional GRN gene for FTD-GRN, so market penetration here means deepening ties with the same frontotemporal dementia research and specialty neurology network, not moving into a new disease area. FTD is rare but serious, and frontotemporal dementia is estimated to account for about 10% to 20% of early-onset dementia cases. For Passage Bio, more investigator referrals, site activity, and advocacy reach around the same indication can raise trial and awareness momentum without changing the core target.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUPenn collaboration leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program is a market-penetration asset: it reinforces scientific credibility and keeps direct access to top gene-therapy expertise in its CNS rare-disease focus.\u003c\/p\u003e\n\u003cp\u003eThat helps Passage Bio deepen trust with clinicians, investigators, and payers without changing its core market.\u003c\/p\u003e\n\u003cp\u003eIn a space where trial quality and platform know-how drive adoption, this UPenn link is a practical way to defend and expand its existing position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCatalent Maryland supply execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio’s development services and clinical supply agreement with Catalent Maryland, Inc. keeps clinical manufacturing tied to one trusted CDMO site, which supports supply continuity for active programs. That matters in market penetration because steady trial supply helps Passage Bio stay visible in the same patient and investigator pools. In rare-disease trials, even one missed shipment can slow enrollment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports ongoing clinical supply\u003c\/li\u003e\n\u003cli\u003eReduces manufacturing disruption risk\u003c\/li\u003e\n\u003cli\u003eKeeps trial presence stable\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePhiladelphia CNS rare-disease base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc., founded in 2017 and headquartered in Philadelphia, Pennsylvania, can push market penetration by deepening ties with the same rare CNS disease community it already knows. Its core remains genetic therapies for central nervous system disorders, so the near-term win is not a new market, but more share of the orphan-disease base and trial footprint already in place. This is a narrow, high-trust niche, where repeat patient, site, and investigator access matters more than broad reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFounded: 2017\u003c\/li\u003e\n\u003cli\u003eHeadquarters: Philadelphia, Pennsylvania\u003c\/li\u003e\n\u003cli\u003eFocus: genetic CNS therapies\u003c\/li\u003e\n\u003cli\u003eBest fit: orphan-disease audience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio Wins by Deepening Rare-Disease Network Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for Passage Bio, Inc. means winning more share inside its current ultra-rare CNS and neurodegeneration network, not expanding into a new market. PBGM01 and PBFT02 both rely on deeper ties with the same pediatric neurology and specialty dementia centers that already know gene therapy. In rare disease, tighter investigator access and faster referral flow can matter more than broad reach.\u003c\/p\u003e\n\u003cp\u003ePassage Bio, Inc. is still a narrow player: founded in 2017 and based in Philadelphia, Pennsylvania, with a core focus on genetic CNS therapies. Frontotemporal dementia is estimated to make up 10% to 20% of early-onset dementia cases, which shows how targeted the field is. The key move is to raise trial visibility, site activity, and patient identification inside the existing network.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBGM01 target\u003c\/td\u003e\n\u003ctd\u003eInfantile GM1 gangliosidosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBFT02 target\u003c\/td\u003e\n\u003ctd\u003eFTD-GRN\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFTD share\u003c\/td\u003e\n\u003ctd\u003e10% to 20% of early-onset dementia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFounded\u003c\/td\u003e\n\u003ctd\u003e2017\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeadquarters\u003c\/td\u003e\n\u003ctd\u003ePhiladelphia, Pennsylvania\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Passage Bio, Inc.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix snapshot for Passage Bio, Inc., helping teams quickly align growth strategy and reduce planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, reputable sources to validate Passage Bio growth assumptions, speeding due diligence and giving a clear reference trail for Ansoff Matrix decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBGM01 referral expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBGM01 referral expansion is a clear market-development move: the therapy stays the same, but Passage Bio, Inc. widens access from a narrow core site base to more GM1 referral channels. That matters because GM1 is ultra-rare, so each added treating center can reach more families and speed diagnosis-to-trial routing. Passage Bio, Inc. has not disclosed a 2026 referral-network count, so the main value is broader patient access for the same asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBFT02 broader FTD-GRN reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBFT02 in FTD-GRN is a market development play: the asset stays the same, but Passage Bio, Inc. broadens investigator reach into more neurology and dementia centers. Frontotemporal dementia affects about 50,000 to 60,000 people in the US, and GRN-linked cases are a small genetic slice, so wider site coverage can matter more than label changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBKR03 Krabbe disease entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBKR03 targets infantile Krabbe disease, an ultra-rare disorder seen in about 1 in 100,000 births, using AAVhu68 and GALC. It opens a new rare-disease patient and clinician segment while reusing Passage Bio, Inc.’s CNS gene-therapy platform. That expands its reach across inherited pediatric neurologic disease without changing the core delivery model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare-disease advocacy channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc. can grow these ultra-rare programs by plugging into patient-advocacy groups, genetic-testing labs, and disease-specific referral centers. That matters because rare diseases affect about 30 million people in the U.S., and 95% still lack an approved treatment, so the best path is wider diagnosis and referral, not new product changes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse advocacy groups to find patients fast.\u003c\/li\u003e\n\u003cli\u003eRoute through genetic testing to confirm cases.\u003c\/li\u003e\n\u003cli\u003eBuild referral links with specialty centers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical-supply enabled site growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Catalent Maryland supply agreement gives Passage Bio, Inc. a clinical-supply backbone for its development programs, which can support faster site expansion without changing the drug asset itself. More trial sites broaden patient access and can lift enrollment for the same pipeline programs, especially in rare-disease studies where each site matters. In Ansoff terms, this is market development: same products, wider reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupply security supports new sites.\u003c\/li\u003e\n\u003cli\u003eMore sites can speed enrollment.\u003c\/li\u003e\n\u003cli\u003eSame pipeline, larger trial reach.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio Expands Reach in Ultra-Rare Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc. is using market development to widen reach for the same assets: PBGM01 in GM1, PBFT02 in FTD-GRN, and PBKR03 in infantile Krabbe disease. This fits ultra-rare markets, where GM1, FTD-GRN, and Krabbe need more referral paths, not new products. Wider sites, advocacy links, and genetic testing can lift enrollment and diagnosis.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eMarket move\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBGM01\u003c\/td\u003e\n\u003ctd\u003eExpand referrals\u003c\/td\u003e\n\u003ctd\u003eGM1 ultra-rare\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBFT02\u003c\/td\u003e\n\u003ctd\u003eExpand neurology sites\u003c\/td\u003e\n\u003ctd\u003eFTD 50k-60k US\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBKR03\u003c\/td\u003e\n\u003ctd\u003eNew rare segment\u003c\/td\u003e\n\u003ctd\u003eKrabbe 1 in 100k births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003ePassage Bio, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable Ansoff Matrix for Passage Bio, Inc., with actionable growth strategies and risk notes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBML04 MLD program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBML04 adds metachromatic leukodystrophy (MLD) to Passage Bio, Inc.'s CNS rare-disease pipeline, so it fits Product Development in the Ansoff Matrix. It brings a new therapeutic program to the company’s existing market and expands the portfolio beyond its current lead assets. This move deepens exposure to a rare disease area with a global MLD incidence often cited at about 1 in 40,000 to 1 in 160,000 births.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBAL05 ALS program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBAL05 is Passage Bio, Inc.'s ALS gene-therapy program, so it extends the Company’s neurodegeneration pipeline into a second high-need disease area. ALS affects about 30,000 people in the U.S., and the move adds one more candidate to the product set while staying in the same CNS-focused market. In Ansoff terms, this is product development, not market expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBCM06 CMT2A program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBCM06 expands Passage Bio, Inc.’s inherited neurologic disease franchise into Charcot-Marie-Tooth type 2A, a rare disorder that affects about 1 in 2,500 people worldwide. This is classic product development in the Ansoff Matrix: a new product for an existing therapeutic focus. It also broadens the pipeline across multiple high-unmet-need indications, which can reduce single-asset risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAAVhu68 payload reuse\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePBGM01 and PBKR03 both use the proprietary AAVhu68 capsid, so Passage Bio, Inc. can reuse one validated delivery platform across new gene-therapy constructs. That means the same development engine can support more candidates with less rework, faster build cycles, and a lower technical learning curve.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne capsid, two lead programs\u003c\/li\u003e\n\u003cli\u003eReuse cuts early development friction\u003c\/li\u003e\n\u003cli\u003eShared platform speeds new constructs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAAV1 brain delivery expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePBFT02 uses AAV1 to deliver GRN into the brain, giving Passage Bio, Inc. a second CNS delivery base next to AAVhu68. That matters for product development, because it broadens vector choice, tissue targeting, and future pipeline design. In 2025 filings, Passage Bio, Inc. still framed these capsids as core platform assets for repeatable CNS programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAAV1 adds a second brain delivery path.\u003c\/li\u003e\n\u003cli\u003eAAVhu68 stays the CNS anchor.\u003c\/li\u003e\n\u003cli\u003ePlatform know-how can speed new programs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio Expands Rare-Disease Pipeline with Reusable Gene-therapy Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc.’s Product Development strategy adds new gene-therapy programs, not new customer markets, so it fits the Ansoff Matrix well. PBML04, PBAL05, PBCM06, PBGM01, PBKR03, and PBFT02 all expand the CNS rare-disease pipeline around shared vectors, including AAVhu68 and AAV1, which can lower build time and reuse platform know-how.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBML04\u003c\/td\u003e\n\u003ctd\u003eMLD\u003c\/td\u003e\n\u003ctd\u003eNew product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBAL05\u003c\/td\u003e\n\u003ctd\u003eALS\u003c\/td\u003e\n\u003ctd\u003eNew product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSix-program pipeline spread\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s six-program pipeline, PBGM01, PBFT02, PBKR03, PBML04, PBAL05, and PBCM06, shows real diversification across rare-disease targets. Instead of relying on one lead asset, Company Name spreads clinical and biological risk across multiple programs, which can soften the impact if one trial stalls. This broader mix is more resilient, especially for a company with a small market cap and limited cash runway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGM1 and FTD-GRN mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc.’s GM1 and FTD-GRN mix spreads risk across two distinct orphan markets. Infantile GM1 gangliosidosis affects roughly 1 in 100,000 to 1 in 200,000 births, while FTD overall impacts about 50,000 to 60,000 Americans, with GRN-linked cases reaching different neurology centers and caregivers. That broadens reach beyond one small patient pool and one specialist network.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKrabbe and MLD lysosomal expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBKR03 and PBML04 push Passage Bio into adjacent lysosomal storage disorder markets, broadening the pipeline beyond one disease and deepening its inherited-metabolic-disease reach. That matters because lysosomal storage disorders span 70+ rare inherited diseases, so each new asset can open a distinct, high-unmet-need niche while reusing the same gene-therapy platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eALS and CMT2A neuromuscular entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePBAL05 and PBCM06 push Passage Bio, Inc. from lysosomal and FTD work into ALS and CMT2A, so the pipeline now spans motor-neuron and peripheral-nerve disease. ALS affects about 30,000 people in the US, and Charcot-Marie-Tooth disease is often cited at about 1 in 2,500 people, so the addressable neurologic pool is wider.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew entry: motor-neuron and peripheral-nerve disease\u003c\/li\u003e\n\u003cli\u003eDifferent from lysosomal and FTD programs\u003c\/li\u003e\n\u003cli\u003eBroader neurologic coverage and market reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBrain plus peripheral tissue delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc. is widening diversification by pairing PBGM01, which is designed to reach both brain and peripheral tissues, with PBFT02, which is brain-focused. That broadens the company from one CNS path into multiple delivery and disease settings. It is both scientific diversification and market diversification across CNS and neuromuscular uses.\u003c\/p\u003e\n\u003cp\u003eOne platform now addresses two tissue maps, which can lift the addressable patient pool and reduce single-asset risk. For an early-stage gene therapy group, that mix matters more than near-term revenue because pipeline breadth often drives value before sales do.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePBGM01: brain plus peripheral tissue delivery\u003c\/li\u003e\n\u003cli\u003ePBFT02: brain-only delivery\u003c\/li\u003e\n\u003cli\u003eBroader CNS and neuromuscular reach\u003c\/li\u003e\n\u003cli\u003eLower dependence on one disease profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio Spreads Risk Across Six Rare-Disease Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc. uses diversification by spreading risk across six programs and four disease areas, from GM1 and FTD-GRN to ALS and CMT2A. That lowers single-asset dependence and widens reach across rare-disease clinics. ALS affects about 30,000 people in the US, while CMT is often cited at 1 in 2,500.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eScope\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBGM01\u003c\/td\u003e\n\u003ctd\u003eCNS + peripheral\u003c\/td\u003e\n\u003ctd\u003eBroader tissue reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBFT02\u003c\/td\u003e\n\u003ctd\u003eBrain-focused\u003c\/td\u003e\n\u003ctd\u003eDifferent delivery map\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBAL05\/PBCM06\u003c\/td\u003e\n\u003ctd\u003eALS\/CMT2A\u003c\/td\u003e\n\u003ctd\u003eNew neurologic markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234832326921,"sku":"pasg-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/pasg-ansoff-matrix.webp?v=1785728148","url":"https:\/\/dcfanalyst.com\/products\/pasg-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}